Sign In
Buy AUPH
$15.67
+0.280 (+1.82%)
At Close: Jun 03, 2026
Aurinia (AUPH) Moves 13.3% Higher: Will This Strength Last?
04:37am, Tuesday, 05'th Jul 2022
Aurinia (AUPH) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the roa
A Buyout-Driven Pair Trade: Buy Aurinia, Sell Merck (Or Seagen If You Must)
09:22am, Monday, 04'th Jul 2022
The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been asso
Why Aurinia Pharmaceuticals Stock Perked Up Today
08:46pm, Friday, 01'st Jul 2022 The Motley Fool
Another buyout rumor is fueling the company's northward move today.
Why Aurinia Pharmaceuticals Stock Perked Up Today
04:46pm, Friday, 01'st Jul 2022
Another buyout rumor is fueling the company's northward move today.
Aurinia: Redemption On Lupkynis Sales And Possible EMA Approval
02:05pm, Friday, 20'th May 2022
Aurinia and its partner OPEL expect a decision from the EMA in the 2nd half of 2022 on whether or not Lupkynis (voclosporin) will be approved for lupus nephritis in the European territories. About $21
PreMarket Prep Stock Of The Day: Good News From Aurinia Pharmaceuticals In A Down Week
06:59pm, Tuesday, 10'th May 2022 Benzinga
Rarely mentioned in the recent chaos in the markets is the biotech sector. With a heavy emphasis in 2020 and 2021 on finding cures and treatments for COVID-19, major drug approvals from the FDA have b
Aurinia Pharmaceuticals Inc. (AUPH) CEO Peter Greenleaf on Q1 2022 Results - Earnings Call Transcript
12:34pm, Tuesday, 10'th May 2022
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH ) Q1 2022 Earnings Conference Call May 10, 2022 8:30 AM ET Company Participants Dana Lynch - Director of Corporate Communications & Corporate Affairs Peter Gr
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
11:15am, Tuesday, 10'th May 2022 Zacks Investment Research
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aurinia Pharmaceuticals (AUPH) Reports Q1 Loss, Tops Revenue Estimates
08:17am, Tuesday, 10'th May 2022
Aurinia (AUPH) delivered earnings and revenue surprises of -3.85% and 9.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Notice of New Dial-In Numbers for Aurinia Pharmaceuticals First Quarter 2022 Financial and Operational Results on May 10, 2022
04:05pm, Friday, 06'th May 2022
VICTORIA, British Columbia--(BUSINESS WIRE)--Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) (“Aurinia” or the “Company”) announces a change to the dial-in number(s) for the upcoming first quarter
3 Healthcare Companies With Revenue Spiking 100% or More
08:00pm, Monday, 02'nd May 2022 The Motley Fool
Here's why three Fool.com contributors are bullish on Outset Medical, Aurinia Pharmaceuticals, and Shockwave Medical.
Aurinia Pharmaceuticals (AUPH) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
07:02pm, Thursday, 28'th Apr 2022 Zacks Investment Research
Aurinia (AUPH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Analyst Ratings for Aurinia Pharmaceuticals
03:08pm, Thursday, 28'th Apr 2022 Benzinga
Analysts have provided the following ratings for Aurinia Pharmaceuticals (NASDAQ:AUPH) within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
4
NEW YORK, March 12, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) resulting from allegations that Aurinia may have issued materially misleading business information to the investing public.
AUPH INVESTOR NOTICE: ROSEN, A TOP RANKED LAW FIRM, Encourages Aurinia Pharmaceuticals Inc. Investors with Losses to Inquire About Securities Class Action Investigation AUPH
10:53pm, Friday, 11'th Mar 2022 NewMediaWire
AUPH INVESTOR NOTICE:
